Ignite Creation Date:
2025-12-25 @ 3:01 AM
Ignite Modification Date:
2026-01-01 @ 5:21 AM
Study NCT ID:
NCT05155033
Status:
RECRUITING
Last Update Posted:
2025-08-11
First Post:
2021-12-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-18
Start Date Type:
ACTUAL
Primary Completion Date:
2031-09-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-09-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-12-10
First Submit QC Date:
None
Study First Post Date:
2021-12-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-08
Last Update Post Date:
2025-08-11
Last Update Post Date Type:
ACTUAL